NASDAQ:ADTX 5 December 2025 - 21 January 2026

Aditxt shares surged late December 17 after the company filed a definitive proxy for a January 30, 2026, special shareholder meeting. The agenda includes votes on potential share dilution, a reverse stock split, and a rebrand to “bitXbio, Inc.” Traders responded to the capital structure moves, not clinical news.

Aditxt (NASDAQ: ADTX) traded around $3 per share midday December 5, 2025, with a market cap near $1.7 million and only 559,000 shares outstanding. The company reported $2,770 in revenue and a $37.6 million net loss for the first nine months of 2025, holding $163,041 in cash as of September 30. ADTX faces ongoing Nasdaq delisting risk after a 1-for-113 reverse split. Trading remains volatile with heavy short interest.